U.S. Markets open in 4 hrs 4 mins

This chart spells trouble for Pfizer

CNBC: Talking Numbers

Pfizer shares are down nearly 9% in the past 3 months and severely lagging the broader market. Why it could get worse for the pharmaceutical giant.